We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Comparing Megestrol Acetate Therapy with Oxandrolone Therapy for HIV-Related Weight Loss: Similar Results in 2 Months.
- Authors
Mwamburi, D. Mkaya; Wilson, Ira B.; Chang, Hong; Scully, Ed; Saboori, Shiva; Miller, Laurel; Forfia, Janet; Albrecht, Mary; Wanke, Christine A.; Gerrior, Jül
- Abstract
Weight loss is known to impact survival among patients infected with human immunodeficiency virus (HIV) even in the era of highly active antiretroviral therapy (HAART). In a randomized trial, we compared the effects of 2 months of treatment with either megestrol acetate (800 mg every day) or oxandrolone (10 mg twice per day) on body weight and composition in patients with weight loss of ≥5 kg who were receiving HAART. The mean weight was 66 kg, and the mean body mass index was 21. Mean weight gain in the megestrol acetate and the oxandrolone arms were 2.8 kg (4.6% of the baseline value) and 2.5 kg (3.9% of the baseline value), respectively (P = .80 ). Lean body mass accounted for 39% of weight gain in the megestrol acetate arm and Pp.80 56% in the oxandrolone arm (P = .38 ). Seven patients in the megestrol acetate arm and 5 patients in the Pp.38 oxandrolone arm reported minor adverse events (P = .74 ). In conclusion, megestrol acetate therapy and Pp.74 oxandrolone therapy have similar effects on body weight and composition and are safe and well-tolerated during HAART.
- Subjects
THERAPEUTICS; HIV infections; WEIGHT loss; ANTIRETROVIRAL agents; WEIGHT gain; DRUG side effects
- Publication
Clinical Infectious Diseases, 2004, Vol 38, Issue 6, p895
- ISSN
1058-4838
- Publication type
Article
- DOI
10.1086/381977